Katayama S, Nishizawa K, Hirano M, Yamamura S, Momose Y
Department of Pharmacy, Medical School Hospital, Sendagi 1-1-5 Bunkyo-ku, Tokyo 113-8602, Japan. Katayama_Sirou/
J Pharm Pharm Sci. 2000 Jan-Apr;3(1):114-7.
The purpose of this work was to investigate the potential effectiveness of polaprezinc in the treatment of stomatitis. Its effect on oral mucous membrane lesions was studied focusing on acetic acid-induced stomatitis in an animal model.
Stomatitis was induced in hamsters by local injection of 30 microL of 10% acetic acid solution into both cheek pouches. Change of the size of the acetic acid-induced white lesion caused by polaprezinc injection was compared with that of control (water injection). The process of healing of damaged membrane was also investigated histopathologically. Selective adhesion of polaprezinc on mucous membrane was studied using color development by complexation between zinc and dithizone.
On day 4 after acetic acid injection, round white lesions were observed in the central area of both pouches. Observation on days 7, 10, and 14 showed that the size of the lesions decreased with time. Comparison with the control group of animals, in which healing took place naturally, showed that daily administration of polaprezinc (10 mg/kg) applied to the cheek pouches significantly promoted healing of the lesion from day 7 onward. Histopathological investigation of the mucous membrane in the cheek pouches 7 days after the induction of stomatitis by acetic acid injection showed thickening, and cell damage was evident. In the group of animals treated with polaprezinc, the thickening of the mucous membrane was less than that in animals of the group receiving no treatment and regeneration of damaged tissue was observed after 6 days of polaprezinc treatment.
Polaprezinc is an effective treatment in this animal model of acetic acid-induced stomatitis. This suggests that the drug may be useful in promoting healing of stomatitis in the clinical setting. Extrapolating these to humans suggests that the drug has healing effect to severe stomatitis induced by anticancer drug therapy.
本研究旨在探讨聚普瑞锌治疗口腔炎的潜在疗效。通过动物模型，重点研究其对醋酸诱导的口腔炎所致口腔黏膜损伤的影响。
通过向仓鼠双侧颊囊局部注射30微升10%醋酸溶液诱导口腔炎。将注射聚普瑞锌后醋酸诱导的白色损伤大小变化与对照组（注射水）进行比较。还通过组织病理学研究受损黏膜的愈合过程。利用锌与双硫腙络合显色研究聚普瑞锌在黏膜上的选择性黏附。
醋酸注射后第4天，双侧颊囊中央区域出现圆形白色损伤。第7、10和14天的观察表明，损伤大小随时间减小。与自然愈合的动物对照组相比，从第7天起，每天向颊囊施用聚普瑞锌（10毫克/千克）可显著促进损伤愈合。醋酸注射诱导口腔炎7天后，对颊囊黏膜进行组织病理学检查，发现黏膜增厚，细胞损伤明显。在聚普瑞锌治疗组动物中，黏膜增厚程度低于未治疗组动物，聚普瑞锌治疗6天后观察到受损组织再生。
在该醋酸诱导的口腔炎动物模型中，聚普瑞锌是一种有效的治疗药物。这表明该药物在临床环境中可能有助于促进口腔炎的愈合。将这些结果外推至人类提示，该药物对抗癌药物治疗引起的严重口腔炎具有愈合作用。
